Classification and Genetic Defects of Diabetes

 
Diagnosis of
Type 1 Diabetes
 
 
1
 
Differential Diagnosis of Type 1
and Type 2 Diabetes
 
2
 
GADA, glutamic acid decarboxylase; HLA, human leukocyte antigen; IAA, autoantibodies to insulin; IA-2A, tyrosine phosphatase insulinoma
antigen; ZnT8A, zinc transporter 8.
*Needs to be refined for nonwhite population groups.
Rewers M. 
Diabetes Metab J
. 2012;36:90-
9
7
.
 
Classifying Diabetes
 
3
 
GADA, glutamic acid decarboxylase; HLA, human leukocyte antigen; IAA, autoantibodies to insulin; IA-2A, the tyrosine phosphatase insulinoma
antigen; ZnT8A, zinc transporter 8; T1aD, type 1 (immune-mediated)  diabetes; T1bD, type 1 (idiopathic) diabetes; T2D, type 2 diabetes.
*Needs to be refined for nonwhite population groups.
Rewers M. 
Diabetes Metab J. 
2012;36:90-97.
 
Etiologic Classification of
Diabetes
 
4
 
APS1, autoimmune polyendocrine syndromes 1; HLA, human leukocyte antigen; IPEX, immunodeficiency, polyendocrinopathy,
enteropathy, X-linked syndrome; LADA, latent autoimmune diabetes of adults; MODY, maturity-onset diabetes of the young; PNDM,
permanent neonatal diabetes mellitus.
Rewers M. 
Diabetes Metab J. 
2012;36:90-
9
7.
 
Genetic Defects of 
-Cell
Function
 
Chromosome 12, HNF-1
α
 (MODY3)
Chromosome 7, glucokinase (MODY2)
Chromosome 20, HNF-4
α
 (MODY1)
 Chromosome 13, insulin promoter factor-1
(IPF-1; MODY4)
Chromosome 17, HNF-1
β
 (MODY5)
Chromosome 2, NeuroD1 (MODY6)
Mitochondrial DNA
 
5
 
ADA.
 Diabetes Care.
 2014;37 (suppl 1):S81-S90.
 
Immune-Mediated Diabetes
(T1a Diabetes)
 
-
C
e
l
l
 
D
e
s
t
r
u
c
t
i
o
n
 
Variable rate
Rapid in infants and
children (primarily)
Slow in adults (primarily)
 
I
m
m
u
n
e
 
M
a
r
k
e
r
s
 
Islet cell autoantibodies
Autoantibodies to insulin
Autoantibodies to GAD
(GAD65)
Autoantibodies to the
tyrosine phosphatases
IA-2 and IA-2b
 
6
When fasting hyperglycemia is first detected, 85% – 90% of
individuals have ≥1 autoantibody
 
ADA.
 Diabetes Care.
 2014;37 (suppl 1):S81-S90.
 
Genetic Markers
 
Strong HLA associations, with linkage to the
DQA and DQB genes
Influenced by the DRB genes
HLA-DR/DQ alleles can be either
predisposing or protective
 
7
 
HLA, human leukocyte antigen.
ADA.
 Diabetes Care.
 2014;37 (suppl 1):S81-S90.
 
Symptoms and Severity of T1D
at Presentation
 
8
 
 
DKA, diabetic ketoacidosis; T1D, type 1 diabetes.
Levy-Marchal C, et al. 
Diabetologia
. 2001;44 (Suppl 3):B75-B80.
 
E
U
R
O
D
I
A
B
(
N
=
1
2
6
0
)
 
T1D Age at Diagnosis Among
Youth
 
9
 
Mayer-Davis EJ, et al. 
N Engl J Med
. 2017;376:1419-1429.
 
S
E
A
R
C
H
 
f
o
r
 
D
i
a
b
e
t
e
s
 
i
n
 
Y
o
u
t
h
Y
o
u
t
h
 
A
g
e
 
1
9
 
Y
e
a
r
s
,
 
2
0
1
2
Individuals ≥20 years of age may also develop T1D.
 
R
a
t
e
 
(
p
e
r
 
1
0
0
,
0
0
0
 
p
e
r
 
y
e
a
r
)
 
Immunological Changes and
Incidence of Type 1 Diabetes
 
Rising incidence of T1D is associated with
altered immunophenotype at diagnosis
Prevalence of IA-2A and ZnT8A has
increased significantly
IAA and GADA prevalence and levels have
not changed
Suggests T1D is  now characterized by a
more intense humoral autoimmune response
 
 
10
 
IAA, autoantibodies to insulin; GADA, GAD; IA-2A, islet antigen-2; T1D, type 1 diabetes; ZnT8A, zinc transporter 8.
 
Long AE, et al. 
Diabetes
. 2012;61:683-
68
6.
 
First manifestation of T1D
in many patients,
especially children and
adolescents
May be precipitated by
infection or environmental
triggers
Rapid change from modest
fasting hyperglycemia to
severe hyperglycemia
 
In some patients
(especially adults),
residual 
β
-cell function
may prevent ketoacidosis
for many years
Once patients become
insulin dependent (with low
or undetectable plasma C-
peptide), they are at risk for
ketoacidosis
 
Ketoacidosis in 
T1D
 
11
 
T1D, type 1 diabetes.
ADA.
 Diabetes Care.
 2014;37 (suppl 1):S81-S90.
 
T1D and Obesity
 
Although T1D patients are rarely obese when
they present, the presence of obesity is not
incompatible with T1D
 
12
 
T1D, type 1 diabetes.
ADA.
 Diabetes Care.
 2014;37 (suppl 1):S81-S90.
 
T1D: Clinical Course
 
Typically characterized by the acute onset of
the classic symptoms of diabetes
Polyuria, polydipsia, weight loss
Course of autoimmune diabetes
characterized by ongoing 
β
-cell destruction
Exogenous insulin required for survival
T1D should be identified as soon as possible to
avoid high morbidity due to a delay in insulin
treatment
 
 
13
 
T
1
D
,
 
t
y
p
e
 
1
 
d
i
a
b
e
t
e
s
.
ADA.
 Diabetes Care.
 2014;37 (suppl 1):S81-S90.
 
T1D and Susceptibility to Other
Autoimmune Diseases
 
Addison
s disease
Autoimmune hepatitis
Celiac sprue
Graves
 disease
Hashimoto
s thyroiditis
Myasthenia gravis
Pernicious anemia
Vitiligo
 
14
 
T1D, type 1 diabetes.
ADA.
 Diabetes Care.
 2014;37 (suppl 1):S81-S90.
 
Idiopathic Diabetes
(Type 1b Diabetes)
 
No known etiology
Strongly inherited
No immunological evidence for 
β
-cell
autoimmunity and no HLA association
More common with African or Asian ancestry
Patient presentation
May have permanent insulinopenia
Prone to ketoacidosis, with varying degrees of
insulin deficiency between episodes
 
15
 
ADA.
 Diabetes Care.
 2014;37 (suppl 1):S81-S90.
 
Fulminant T1D
 
Presentation
Extremely high glucose levels with diabetic
ketoacidosis
On average only 4 days of hyperglycemia
Normal or near-normal A1C
Often preceded by common cold–like and
gastrointestinal symptoms
Sometimes associated with pregnancy
Pancreatic enzymes often elevated
 
16
 
T1D, type 1 diabetes.
Hanafusa T, Imagawa A. 
Nat Clin Pract Endocrinol Metab
. 2007;3:36-45.
Slide Note
Embed
Share

The diagnosis and differential diagnosis of Type 1 and Type 2 diabetes are discussed, detailing the clinical courses, age of onset, body weight characteristics, onset patterns, and genetic factors. The etiologic classification of diabetes including insulin-deficient, immune-mediated, monogenic, and polygenic types is explained along with genetic defects in beta-cell function across different chromosomes. This comprehensive overview provides insights into the various aspects of diabetes classification and genetic mechanisms involved.

  • Diabetes classification
  • Genetic defects
  • Type 1 diabetes
  • Type 2 diabetes
  • Beta-cell function

Uploaded on Jul 27, 2024 | 0 Views


Download Presentation

Please find below an Image/Link to download the presentation.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.

E N D

Presentation Transcript


  1. Diagnosis of Type 1 Diabetes 1

  2. Differential Diagnosis of Type 1 and Type 2 Diabetes Type 1 Diabetes Type 2 Diabetes Usual clinical course Insulin-dependent Initially non-insulin-dependent Usual age of onset <20 years (but ~50% over 20 years) >40 years but increasingly earlier Body weight Often lean but ~50% overweight or obese Usually obese Onset Often acute Subtle, slow Ketosis prone Yes 15% with 1st-degree relative No Family history Common Frequency of HLA-DR3, DR4, DQB1*0201, *0302 Increased Not increased Islet autoantibodies (GADA, ICA, IA-2A, IAA, ZNT8A) Present Absent GADA, glutamic acid decarboxylase; HLA, human leukocyte antigen; IAA, autoantibodies to insulin; IA-2A, tyrosine phosphatase insulinoma antigen; ZnT8A, zinc transporter 8. *Needs to be refined for nonwhite population groups. 2 Rewers M. Diabetes Metab J. 2012;36:90-97.

  3. Classifying Diabetes Autoantibody negative at onset High-risk HLA* DR3/4, DQ1B1*0302, DR4/4, DR4/8, DR3/3 (10% of T1D population) IAA+ GADA+ IA-2A+ or ZnT8A+ C-peptide (ng/mL) <1.0 1.0 HLA+ T1aD = 80% T1bD 5% T2D 10% HLA- GADA, glutamic acid decarboxylase; HLA, human leukocyte antigen; IAA, autoantibodies to insulin; IA-2A, the tyrosine phosphatase insulinoma antigen; ZnT8A, zinc transporter 8; T1aD, type 1 (immune-mediated) diabetes; T1bD, type 1 (idiopathic) diabetes; T2D, type 2 diabetes. *Needs to be refined for nonwhite population groups. 3 Rewers M. Diabetes Metab J. 2012;36:90-97.

  4. Etiologic Classification of Diabetes Insulin deficient Insulin deficient/resistant Immune mediated Nonimmune mediated Monogenic Polygenic Type 1a Type 1b MODY PNDM Type 2 Typical (HLA-DR3, 4, or 9) Slow progressing LADA APS1, IPEX Fulminant Idiopathic HNF4A GCK HNF1A, 1B PDX1 NeuroD1 KCNJ11 ABCC8 INS PTF1A EIF2AK3 ~5% 20% of all DM APS1, autoimmune polyendocrine syndromes 1; HLA, human leukocyte antigen; IPEX, immunodeficiency, polyendocrinopathy, enteropathy, X-linked syndrome; LADA, latent autoimmune diabetes of adults; MODY, maturity-onset diabetes of the young; PNDM, permanent neonatal diabetes mellitus. 4 Rewers M. Diabetes Metab J. 2012;36:90-97.

  5. Genetic Defects of -Cell Function Chromosome 12, HNF-1 (MODY3) Chromosome 7, glucokinase (MODY2) Chromosome 20, HNF-4 (MODY1) Chromosome 13, insulin promoter factor-1 (IPF-1; MODY4) Chromosome 17, HNF-1 (MODY5) Chromosome 2, NeuroD1 (MODY6) Mitochondrial DNA 5 ADA. Diabetes Care. 2014;37 (suppl 1):S81-S90.

  6. Immune-Mediated Diabetes (T1a Diabetes) -Cell Destruction Variable rate Rapid in infants and children (primarily) Slow in adults (primarily) Immune Markers Islet cell autoantibodies Autoantibodies to insulin Autoantibodies to GAD (GAD65) Autoantibodies to the tyrosine phosphatases IA-2 and IA-2b When fasting hyperglycemia is first detected, 85% 90% of individuals have 1 autoantibody 6 ADA. Diabetes Care. 2014;37 (suppl 1):S81-S90.

  7. Genetic Markers Strong HLA associations, with linkage to the DQA and DQB genes Influenced by the DRB genes HLA-DR/DQ alleles can be either predisposing or protective HLA, human leukocyte antigen. 7 ADA. Diabetes Care. 2014;37 (suppl 1):S81-S90.

  8. Symptoms and Severity of T1D at Presentation EURODIAB (N=1260) Presenting Symptoms DKA at Presentation 96% 100 100 90 90 80 80 70 70 61% Patients (%) Patients (%) 60 60 52% 50 50 42% 40 40 30 30 33% with pH 7.1-7.3 20 20 9% 10 10 9% with pH <7.1 0 0 Polyuria Weight Loss Fatigue Severe DKA DKA DKA, diabetic ketoacidosis; T1D, type 1 diabetes. 8 Levy-Marchal C, et al. Diabetologia. 2001;44 (Suppl 3):B75-B80.

  9. T1D Age at Diagnosis Among Youth SEARCH for Diabetes in Youth Youth Age 19 Years, 2012 Cases per 100,000 youths/year 35 Rate (per 100,000 per year) 31.8 27.7 30 25 20 14.3 12.9 15 10 5 0 0-4 5-9 10-14 14-19 Individuals 20 years of age may also develop T1D. 9 Mayer-Davis EJ, et al. N Engl J Med. 2017;376:1419-1429.

  10. Immunological Changes and Incidence of Type 1 Diabetes Rising incidence of T1D is associated with altered immunophenotype at diagnosis Prevalence of IA-2A and ZnT8A has increased significantly IAA and GADA prevalence and levels have not changed Suggests T1D is now characterized by a more intense humoral autoimmune response IAA, autoantibodies to insulin; GADA, GAD; IA-2A, islet antigen-2; T1D, type 1 diabetes; ZnT8A, zinc transporter 8. 10 Long AE, et al. Diabetes. 2012;61:683-686.

  11. Ketoacidosis in T1D First manifestation of T1D in many patients, especially children and adolescents May be precipitated by infection or environmental triggers Rapid change from modest fasting hyperglycemia to severe hyperglycemia In some patients (especially adults), residual -cell function may prevent ketoacidosis for many years Once patients become insulin dependent (with low or undetectable plasma C- peptide), they are at risk for ketoacidosis T1D, type 1 diabetes. 11 ADA. Diabetes Care. 2014;37 (suppl 1):S81-S90.

  12. T1D and Obesity Although T1D patients are rarely obese when they present, the presence of obesity is not incompatible with T1D T1D, type 1 diabetes. 12 ADA. Diabetes Care. 2014;37 (suppl 1):S81-S90.

  13. T1D: Clinical Course Typically characterized by the acute onset of the classic symptoms of diabetes Polyuria, polydipsia, weight loss Course of autoimmune diabetes characterized by ongoing -cell destruction Exogenous insulin required for survival T1D should be identified as soon as possible to avoid high morbidity due to a delay in insulin treatment T1D, type 1 diabetes. 13 ADA. Diabetes Care. 2014;37 (suppl 1):S81-S90.

  14. T1D and Susceptibility to Other Autoimmune Diseases Addison s disease Autoimmune hepatitis Celiac sprue Graves disease Hashimoto s thyroiditis Myasthenia gravis Pernicious anemia Vitiligo T1D, type 1 diabetes. 14 ADA. Diabetes Care. 2014;37 (suppl 1):S81-S90.

  15. Idiopathic Diabetes (Type 1b Diabetes) No known etiology Strongly inherited No immunological evidence for -cell autoimmunity and no HLA association More common with African or Asian ancestry Patient presentation May have permanent insulinopenia Prone to ketoacidosis, with varying degrees of insulin deficiency between episodes 15 ADA. Diabetes Care. 2014;37 (suppl 1):S81-S90.

  16. Fulminant T1D Presentation Extremely high glucose levels with diabetic ketoacidosis On average only 4 days of hyperglycemia Normal or near-normal A1C Often preceded by common cold like and gastrointestinal symptoms Sometimes associated with pregnancy Pancreatic enzymes often elevated T1D, type 1 diabetes. 16 Hanafusa T, Imagawa A. Nat Clin Pract Endocrinol Metab. 2007;3:36-45.

More Related Content

giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#giItT1WQy@!-/#